“ALLOKINE-ALPHA” MUST STOP DISSEMINATING INFORMATION ABOUT ITS EFFICACY FROM COVID-19

04-05-2020 | 12:48

Information about “Allkolin-Alpha” on the  medication web-site emphasized its efficacy in prophylactics and treatment of the new coronavirus infection. However, it is corroborated with neither clinical trials nor details of the Instructions for use

 

As established by Moscow OFAS, “Brand-Pharma” Ltd. published a letter from “Alvils” Ltd. on allokin.ru, addressed to medical facilities but accessible by any site visitor. The letter highlighted that using “Allkolin-Alpha” to treat mild and moderate-severe COVID-19 allegedly shortens the period of eliminating virus from blood cells and prevents development of life-threatening conditions in most patients. The letter reported about positive results of treatment with “Allkolin-Alpha” to prevent disease prevalence among medical workers.

 

The list of indications in the instruction for use of the medicine, however, does not mention COVID-19. Furthermore, the letter of “Alvils” Ltd. published on allokin.ru, and other sources do not confirm the efficacy of “Allkolin-Alpha” against the new coronavirus infection COVID-19, corroborated with research findings or clinical trials.

 

At the same time, description of the general  medicine characteristics, its composition and effect upon the human body cannot form the grounds for a firm conclusion about the efficacy of “Allkolin-Alpha” for treating the new coronavirus infection.

According to Moscow OFAS, “Brand-Pharma” Ltd. and “Alvils” Ltd. can mislead the population regarding positive effects of “Allkolin-Alpha” in treating patients with COVID-19 and people who are in contact with COVID-19 patients.

 

Based on it, the antimonopoly authority issued a warning to the companies to terminate actions that have elements of unfair competition – the companies must stop disseminating unreliable information.

 

If “Brand-Pharma” Ltd. and “Alvils” Ltd. fail to execute the warning before the deadline, an antimonopoly case shall be opened. If an act of unfair competition is proven, companies shall be held administratively liable and fined up to 500,000 RUB.



Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements International Working Groups Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Concept Note Meetings OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD EEU Model Law on Competition ICN BRICS BRICS Conferences Documents BRICS Coordination Committee on antimonopoly policy BRICS Working Groups for the research of competition issues in socially important markets Cooperation within the BRICS BRICS Coordination Committee on antimonopoly policy EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide COVID-19